| Company Profile |  | 0-9 | | A | | B | | C | | D | | E | | F | | G | | H | | I | | J | | K | | L | | M | | N | | O | | P | | Q | | R | | S | | T | | U | | V | | W | | X | | Y | | Z |
Program Information Company Profile Company Market News Interactive Charting Company Financials Company Calendar of Events DR Program News/Events Company Books Close / Open Notices Company Capital Raisings Company Certification Papers Company Corporate Actions Company Dividends / GDN Interest Payments Company DSF Notices Shareholder Information Estimated Fee Calculator
Company Profile
|
Evaxion Biotech A/S
(NASDAQ: EVAX)
|
2:57 PM UTC, 04/22/25 | |||
|---|---|---|---|---|
| Last: $1.32 | Change: +0.01 | %Change: +1.15% | Volume: 14,736 | |
Detailed Quote
M = Million B = Billion
Price Performance
Management Effectiveness
Profitability
| Open: | $ 1.31 | Volume: | 14,736 | |
|---|---|---|---|---|
| High: | $ 1.32 | Yield(%) | 0.00 | |
| Low: | $ 1.28 | P/E Ratio (ttm): | n/a | |
| Dividend ($): | n/a | Market Cap ($): | 1.84M | |
| EPS ($) | -14.54 | Shares Out: | 1.40M |
DR Program Information
| Company name | Evaxion Biotech A/S |
| Current Book Status | |
| CUSIP | 29970R303 (Active) |
| Ratio (ORD:DRS) | 50 :1 |
| DR Ticker | EVAX |
| ORD Ticker | |
| DR ISIN | US29970R303 |
| ORD ISIN | DK009A6B5E45 |
| Sedol | |
| DR Type | ADR |
| Country | Denmark |
| Active Date | 2/9/2021 |
| Inactive Date | |
| GICS Industry | Biotech & Pharma |
| Depositary | BoNY (Sponsored) |
| Unsponsored Depositaries | |
| Custodians | |
| Flags | Single-listed |
| Product Milestones | Ratio change (old: 10 ORD: 1 ADS) CUSIP (old: 29970R204) due to reverse split effective 1/13/2025. |
| Comments |
| % Price Change (last 4 weeks): | -29.46 |
|---|---|
| % Price Change (last 13 weeks): | -57.77 |
| % Price Change (last 26 weeks): | -89.72 |
| % Price Change (last 52 weeks): | -93.77 |
| % Price Change (year to date): | -69.01 |
| Return on Equity (%): | n/a |
|---|---|
| Return on Assets (%): | -83.16 |
| Return on Invested Capital (%): | -145.28 |
| Gross Profit Margin (%): | n/a |
|---|---|
| Net Profit Margin (%): | -316.00 |
| Operating Profit Margin (%): | -440.55 |
Price & Volume
Company Information
Per Share Data
Valuation Ratios
Financial Strength
|
|
|
| 50-day Moving Average: | $1.92 |
|---|---|
| 200-day Moving Average: | $8.75 |
| Avg. Daily Vol. (last 50 days): | 152,244 |
| Avg. Daily Vol. (last 200 days): | 746,398 |
| 52-wk high: | $21.80 |
| 52-wk low: | $1.20 |
| Bid: | $1.31 |
| Ask: | $1.32 |
|
Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.
|
|
Evaxion Biotech A/S
Dr. Neergaards Vej 5F Hoersholm ND 2970 Phone: 45.53.53.18.50 Fax: n/a http://www.evaxion-biotech.com |
| Earnings (1year) ($): | -14.54 |
|---|---|
| Annual Dividend ($): | 0.00 |
| Current P/E Ratio (ttm): | n/a |
| Book Value ($): | -1.18 |
| Cash Flow ($): | -7.09 |
| Price/Earnings (x): | n/a |
|---|---|
| Price/Sales (x): | 1.36 |
| Price/Book (x): | n/a |
| Price/Cash Flow (x): | n/a |
| Quick Ratio (x): | 2.01 |
|---|---|
| Current Ratio (x): | 2.01 |
| LT Debt/Equity (x): | n/a |
| Total Debt/Equity (x): | n/a |
